#	Pagina
attuale pagina	/open-fp7/projects/93826/index.html

PROHIBIT

Prevention of Hospital Infections by Intervention and Training

Coordinatore	UNIVERSITE DE GENEVE Organization address address: Rue du General Dufour 24 city: GENEVE postcode: 1211 contact info Titolo: Prof. Nome: Didier Cognome: Pittet Email: send email Telefono: +41 22 372 9828 Fax: +41 22 372 3987
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	3˙887˙004 €
EC contributo	2˙999˙934 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2009-single-stage
Funding Scheme	CP-FP
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-01-01 - 2014-06-30

Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITE DE GENEVE Organization address address: Rue du General Dufour 24 city: GENEVE postcode: 1211 contact info Titolo: Prof. Nome: Didier Cognome: Pittet Email: send email Telefono: +41 22 372 9828 Fax: +41 22 372 3987	CH (GENEVE)	coordinator	883˙042.00
2	RIJKSINSTITUUT VOOR VOLKSGEZONDHEIDEN MILIEU*NATIONAL INSTITUTEFOR PUBLIC HEALTH AND THE ENVIRONMENTEN Organization address address: Antonie Van Leeuwenhoeklaan 9 city: BILTHOVEN postcode: 3721 MA contact info Titolo: Prof. Nome: Hajo Cognome: Grundmann Email: send email Telefono: +31 30 274 4239 Fax: +31 30 274 4409	NL (BILTHOVEN)	participant	985˙908.56
3	CHARITE - UNIVERSITAETSMEDIZIN BERLIN Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 contact info Titolo: Prof. Nome: Petra Cognome: Gastmeier Email: send email Telefono: +49 03 8445 3680 Fax: +49 03 8445 3682	DE (BERLIN)	participant	505˙488.00
4	UNIVERSITAETSKLINIKUM FREIBURG Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 contact info Titolo: Mr. Nome: Gerhard Cognome: Henninger Email: send email Telefono: +49 761 270 1920 Fax: +49 761 270 1889	DE (FREIBURG)	participant	360˙600.00
5	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Mr. Nome: Mike Cognome: Robinson Email: send email Telefono: +44 20 7594 3866 Fax: +44 20 7594 3868	UK (LONDON)	participant	143˙425.45
6	UNIWERSYTET JAGIELLONSKI Organization address address: Ul. Golebia 24 city: KRAKOW postcode: 31007 contact info Titolo: Ms. Nome: Jolanta Cognome: Palowska Email: send email Telefono: +48 12 421 4664 Fax: +48 12 421 4664	PL (KRAKOW)	participant	46˙320.00
7	WORLD HEALTH ORGANIZATION. Organization address address: Avenue Appia 20 city: GENEVE postcode: 1211 contact info Titolo: Dr. Nome: Benedetta Cognome: Allegranzi Email: send email Telefono: +41 22 791 26 89 Fax: +41 22 791 13 88	CH (GENEVE)	participant	44˙550.00
8	Nome Ente NON disponibile Organization address address: ALBERT FLORIAN UTCA 2-6 city: Budapest postcode: 1097 contact info Titolo: Dr. Nome: Emese Cognome: Szilágyi Email: send email Telefono: +36 1 4761178 Fax: +36 1 4761178	HU (Budapest)	participant	25˙800.00
9	CENTRE HOSPITALIER REGIONAL DE MARS EILLE ASSISTANCE PUBLIQUE-HOPITAUX MARSEILLE Organization address address: RUE BROCHIER 80 city: MARSEILLE CEDEX 20 postcode: 13354 contact info Titolo: Prof. Nome: Hervé Cognome: Richet Email: send email Telefono: +33 4 9138 6000	FR (MARSEILLE CEDEX 20)	participant	4˙800.00

Mappa

Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

interventions prevent guidelines survey prevention practices crbsi bloodstream compliance infection healthcare effectiveness hospitals hai catheter

Obiettivo del progetto (Objective)

'The aim of PROHIBIT is to understand existing guidelines and practices to prevent healthcare associated infections (HAI) in European hospitals, identify factors that enable and prevent compliance with best practices, and test the effectiveness of interventions of known efficacy. The project will employ a mixed-methods approach combining the strengths of qualitative research, survey methods, observational and experimental designs. First, we will systematically review current guidelines on prevention of the most common HAIs within the EU, as well as schemes for surveillance and public reporting. Next, we will conduct a large-scale survey of what is actually being done in European hospitals, determining factors, and how these relate to bloodstream infection rates. The project will then focus on catheter-related bloodstream infection (CRBSI), a highly transmissible and reliably measured HAI, in a selected sample of European hospitals. In-depth interviews of healthcare staff and direct observation will be used to measure compliance with key prevention practices. A randomized effectiveness trial using a stepped wedge design will be conducted in intensive care units to determine the uptake and impact of 2 interventions (WHO hand hygiene protocol and so-called catheter bundle) on CRBSI as well as clinical and utilization outcomes. The information will be synthesized to develop recommendations for the EU, policy makers, managers and medical professionals to prevent HAI. Dissemination will include instructional workshops and on-line training materials.'